Evidence map›Paper›PMID 34496010›Full record

ArticleBlood advances2021

Activation status dictates the function of unlicensed natural killer cells in mice and humans.

Ethan G Aguilar, Cordelia Dunai, Sean J Judge, Anthony E Zamora, Lam T Khuat, Logan V Vick, Craig P Collins, Kevin M Stoffel, Maite Alvarez, Isabel Barao and 6 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Deciphering the biology of KIR2DL3Scientific reports · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Ethan G AguilarDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA.ORCID 0000-0002-3600-0913
Cordelia DunaiDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA.ORCID 0000-0001-5799-2387
Sean J JudgeDivision of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, CA.ORCID 0000-0002-1842-9468
Anthony E ZamoraDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA.ORCID 0000-0001-5712-5339
Lam T KhuatDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA.ORCID 0000-0002-4223-8805
Logan V VickDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA.
Craig P CollinsDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA.
Kevin M StoffelDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA.
Maite AlvarezDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA.ORCID 0000-0002-5969-9181
Isabel BaraoDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA.
Jeffrey S MillerDepartment of Medicine, University of Minnesota, Minneapolis, MN.
Bruce R BlazarDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-9608-9841
Patrice ChevallierCentre de Recherche en Cancerologie et Immunologie Nantes-Angers, Universite d'Angers-Universite de Nantes, INSERM, Centre National de la Recherche Scientifique (CNRS), Nantes, France.
Christelle RetiereCentre de Recherche en Cancerologie et Immunologie Nantes-Angers, Universite d'Angers-Universite de Nantes, INSERM, Centre National de la Recherche Scientifique (CNRS), Nantes, France.ORCID 0000-0001-5943-6990
Robert J CanterDivision of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, CA.ORCID 0000-0002-3331-5418
William J MurphyDepartment of Dermatology, UC Davis School of Medicine, Sacramento, CA.ORCID 0000-0002-2793-401X
University of California, Davis · USUniversity of Minnesota · USCentre National de la Recherche Scientifique · FRMedical College of Wisconsin · USNavarre Institute of Health Research · ES

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Immunoregulatory and effector roles of natural killer cell subsetsR01HL140921 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MURPHY, WILLIAM JOSEPH · 2018 to 2021
$1.9M
Shared LSRII Cytometer Equipment Application - UC Davis Stem Cell ProgramS10RR026825 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NOLTA, JAN A. · 2010 to 2010
$500k
NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA093373NCRR NIH HHS S10 RR026825NHLBI NIH HHS R01 HL140921
6 · The paper itself

Abstract

Natural killer (NK) cells are involved in innate defense against viral infection and cancer. NK cells can be divided into subsets based on the ability of different receptors to bind to major histocompatibility (MHC) class 1 molecules, resulting in differential responses upon activation in a process called "licensing" or "arming." NK cells expressing receptors that bind self-MHC are considered licensed due to an augmented effector lytic function capability compared with unlicensed subsets. However, we demonstrated that unlicensed NK subsets instead positively regulate the adaptive T-cell response during viral infections that are related to localization and cytokine production. In this study, the differential effects of the two types of NK subsets were contingent on the environment in viral infection and hematopoietic stem cell transplantation (HSCT) models. Infection of mice with high-dose (HD) murine cytomegalovirus (MCMC) led to a loss of licensing-associated differences, as compared with mice with low-dose (LD) infection: the unlicensed NK subset no longer localized in lymph nodes (LNs), but instead remained at the site of infection. Similarly, the patterns observed during HD infection paralleled the phenotypes of both human and mouse NK cells in an HSCT setting where NK cells exhibit an activated phenotype. However, in contrast to the effects of subset depletion in T-cell replete models, the licensed NK cell subsets still dominated antiviral responses after HSCT. Overall, our results highlight the intricate tuning of NK cells and how it affects overall immune responses with regard to licensing patterns and their dependency on the level of stimulation and activation status.

Indexed as

Hematopoietic Stem Cell TransplantationMuromegalovirusAnimalsHumansKiller Cells, NaturalMiceMice, Inbred C57BL

Identifiers

PMID34496010
PMCPMC8945636
OpenAlexW3198378135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.